A Phase II Study of Talimogene laherparepvec Followed by Talimogene laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin TumorsTrial Description: This phase II trial studies how well talimogene laherparepvec and nivolumab work in treating patients with lymphomas that do not responded to treatment (refractory) or non-melanoma skin cancers that have spread to other places in the body (advanced) or do not responded to treatment. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and nivolumab may work better compared to usual treatments in treating patients with lymphomas or non-melanoma skin cancers.
- Conditions: adenoid cystic skin carcinoma, adnexal carcinoma, anaplastic large cell lymphoma alk-negative, anaplastic large cell lymphoma alk-positive, apocrine carcinoma, cylindrocarcinoma, digital papillary adenocarcinoma, endocrine mucin-producing sweat gland carcinoma, extramammary paget disease, extraocular cutaneous sebaceous carcinoma, hidradenocarcinoma, keratoacanthoma, malignant sweat gland neoplasm, merkel cell carcinoma, microcystic adnexal carcinoma, nk-cell lymphoma unclassifiable, papillary adenocarcinoma, porocarcinoma, primary cutaneous mucinous carcinoma, recurrent mature t-cell and nk-cell non-hodgkin lymphoma, recurrent t-cell non-hodgkin lymphoma, refractory anaplastic large cell lymphoma, refractory mature t-cell and nk-cell non-hodgkin lymphoma, refractory merkel cell carcinoma, refractory mycosis fungoides, refractory primary cutaneous t-cell non-hodgkin lymphoma, refractory skin squamous cell carcinoma, refractory t-cell non-hodgkin lymphoma, sezary syndrome, signet ring cell carcinoma, skin basal cell carcinoma, skin basosquamous cell carcinoma, skin squamous cell carcinoma, spiradenocarcinoma, squamoid eccrine ductal carcinoma, squamous cell carcinoma of unknown primary, sweat gland carcinoma, trichilemmal carcinoma, vulvar squamous cell carcinoma
- Phase: II
- Trial ID: NCT02978625
- Protocol ID: 17-753